| Market Cap | 18.70M | P/E | 0.08 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.27M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 1.24M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -42.00% |
| Recommedations | - | Quick Ratio | 0.06 | Shares Outstanding | 25.93M | 52W Low Chg | 212.00% |
| Insider Own | - | ROA | -47.34% | Shares Float | - | Beta | 0.50 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 1.31 |
| Gross Margin | 32.98% | Profit Margin | -102.67% | Avg. Volume | 4,330 | Target Price | - |
| Oper. Margin | -55.92% | Earnings Date | - | Volume | 125 | Change | -7.20% |
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
